Clinical Trial Update: Clinical Trial of PCV24 in Adults Aged ≥18 Years [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of Phase 1/2 clinical trials of the PCV24 pneumococcal vaccine in adults aged 18 years and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infectious Disease | Phase 1, Phase 2 | Status: COMPLETED